Insider buying last 90 days
No open-market insider purchases were filed for CRL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Charles River Laboratories moves this week on an acquisition and a guidance update. The company has agreed to acquire Frontage Holdings Corporation's bioanalysis and DMPK businesses for up to $545 million, with reports specifying approximately $470 million in cash plus potential additional payments of up to $75 million, with the operations located in Exton, Pennsylvania. Separately, the company raised its 2026 GAAP EPS guidance to $8.15 to $8.35, a move attributed primarily to a third-quarter tax reserve reversal, alongside what coverage describes as mild top-line pressure.
CRL closes at $353.34, up 4.7%, sitting above both its 50-day average of $306.83 and its 200-day average of $225.23, with the 50-day above the 200-day. The stock's one-month return stands at 17.1% and its one-year return at 106.8%, near its 52-week high of $379.63. The GekkoIndex reads 53.5, placing it in the Neutral zone, while price sits 33.8% above Gekko Fair Value of $264.16.
Looking ahead, the next earnings date falls on 17 February 2027, 94 days away and outside a typical 20-trading-day hold. Over the last 30 days, one unusual options signal appears, with put premium of $1,553,540 against call premium of $432,250. Seasonality from this point in the calendar shows the next 20 trading days averaging a 0.4% return over 5 years, rising in 2 of them. Analyst consensus among 15 firms shows 14 buy and 1 hold ratings, with a consensus target of $318.87.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Charles River Laboratories International scores 2 supportive, 2 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed2 headwinds
Above 50 and 200-day
Close $337.97 is above the 50-day ($311.06) and 200-day ($227.71) averages, and the 50-day is above the 200-day.
See the chart56.2, Neutral
Reading 56.2 is in the Neutral zone.
See the GekkoIndex21.7% above
Price is 21.7% above Gekko Fair Value (more than 5% above).
See fair valueLeans bearish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 94 days
Next report Feb 17, 2027, 94 days away — outside a typical 20-trading-day hold.
See earnings+2.5% on average
From this point in the calendar, the next 20 trading days averaged +2.5% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Charles River Laboratories International closed at $337.97 on Nov 13, 2026, +97.1% over the past year, inside a 52-week range of $146.20 to $379.63.
Use the left and right arrow keys to read daily values.
Put CRL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Charles River Laboratories International serves pharmaceutical and biotechnology firms by acting as an outside research partner for the early stages of drug development. Clients turn to it for help discovering new compounds, running non-clinical studies, and confirming that candidate drugs are safe before moving forward, and it has built a name for breeding and supplying laboratory rats and mice used in that experimentation.
Its work is split across three business areas. One focuses on producing research-grade rodents, including genetically modified strains, and on services that help laboratories manage animal colonies, outsource facility operations, and run diagnostics on research animals. Another concentrates on the science behind early drug development, helping clients pinpoint and confirm promising targets, molecules, and antibodies, then evaluating them through toxicology work, pathology review, safety pharmacology, bioanalysis, metabolic profiling, and pharmacokinetic analysis. A third handles testing tied to manufacturing, checking the sterility and quality of drugs and consumer goods, performing specialized biologics testing on behalf of client companies, and supplying materials used in vaccine production, such as disease-free eggs and birds along with related diagnostic tools. Beyond these three areas, the company also operates animal housing facilities under contract for biopharmaceutical clients, and its client base spans the United States, Europe, Canada, and Asia Pacific.
Its shares trade on the NYSE under the ticker CRL.
Charles River Laboratories International’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56.2, in the Neutral zone, up 0.9 points over five sessions.
Up 0.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 45 | −0.7% | +3.2% | ||
| Accumulation | 245 | +1.1% | +3.0% | ||
| Neutral (current zone) | 339 | +0.6% | +2.0% | ||
| Distribution | 66 | −0.6% | −1.5% | ||
| Selling | 7 | Too few readings yet | |||
Average CRL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Charles River Laboratories International trades 21.7% above Gekko Fair Value of $277.70, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Charles River Laboratories International shares are worth, recalculated every trading day.
$277.70
Gekko Fair Value, Nov 14, 2026
21.7% Overvalued
At the end of Aug 2026 the price was 45.1% above the estimate.
No open-market insider purchases were filed for Charles River Laboratories International, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for CRL in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in CRL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Charles River Laboratories International has been buying back its own shares.
From company filings.
1signal, 22% of the flagged premium in calls.
Latest: Bearish flow on Nov 3, $1.99M in unusual premium.
0of the funds Gekko tracks hold CRL.
Charles River Laboratories International reports on Feb 17, 2027, before the open (94 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 17, 2027
Expected before the open, 94 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $3.02 est $2.74 | $1.00B est $977.2M | +13.4% |
| May 7, 2026 | $2.06 est $1.96 | $995.8M est $977.5M | −2.3% |
| Feb 18, 2026 | $2.39 est $2.35 | $994.2M est $987.0M | +3.6% |
| Nov 5, 2025 | $2.43 est $2.32 | $1.00B est $987.2M | −3.9% |
| Aug 6, 2025 | $3.12 est $2.50 | $1.03B est $968.9M | −10.6% |
| May 7, 2025 | $2.34 est $2.06 | $984.2M est $958.8M | +22.5% |
| Feb 19, 2025 | $2.66 est $2.50 | $1.00B est $948.2M | +5.1% |
| Nov 6, 2024 | $2.59 est $2.42 | $1.01B est $976.0M | +11.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Charles River Laboratories International is $346.07, +2.4% from the last close, from 15 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 15 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 11 | TD Cowen | $388 | +14.8% |
| Nov 6 | Mizuho Securities | $315 | −6.8% |
| Nov 5 | Barclays | $375 | +11.0% |
| Nov 5 | Robert W. Baird | $364 | +7.7% |
| Nov 5 | Bank of America Securities | — | — |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Charles River Laboratories International averaged +2.5% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.9% | 1 of 5 |
| Next 10 trading days | +1.2% | 2 of 5 |
| Next 15 trading days | −0.2% | 2 of 5 |
| Next 20 trading days | +2.5% | 2 of 5 |
| Next 30 trading days | +6.0% | 2 of 5 |
For scale, CRL’s typical 20-trading-day move in either direction is about 8%.
Charles River Laboratories International’s market cap is $16.19B, with a P/E ratio of 370.5 and revenue of $3.98B over the last twelve months.
Coverage of Charles River Laboratories International this week reads positive: 7 positive, 3 neutral and 0 negative headlines.
Charles River Laboratories International’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| SHOPShopify | Accumulation | 0.6% above |
| CTASCintas | Neutral | 22.3% above |
| PYPLPayPal | Neutral | 5.3% above |
| XYZBlock | Neutral | 15.1% above |
| FISVFiserv | Distribution | 38.0% below |
| CPAYCorpay | Distribution | 5.1% below |
A peer links to its own page where one exists.
Charles River Laboratories International’s market cap is $16.19B at the Nov 13, 2026 close of $337.97, with 47.92M shares outstanding. The shares trade on a P/E ratio of 370.5.
The consensus analyst 12-month price target for Charles River Laboratories International is $346.07, +2.4% from the last close. Of the 15 firms that rated the stock in the last 90 days, 14 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Charles River Laboratories International is overvalued: the Nov 13, 2026 close of $337.97 is 21.7% above Gekko Fair Value of $277.70. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Charles River Laboratories International is expected to report on Feb 17, 2027, before the market opens (94 days away). Analysts expect earnings of $3.32 per share on revenue of $970.2M. Charles River Laboratories International beat the earnings estimate in 8 of its last 8 reports, moving 9.1% on average across the report.
Charles River Laboratories International’s 52-week high is $379.63 and its 52-week low is $146.20; it closed at $337.97 on Nov 13, 2026, +97.1% over the past year. Over the last five years the shares peaked at $397.77 on Nov 16, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 6 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 2 as headwinds (fair value and smart money). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Charles River Laboratories International over the last 30 days, with $432K of flagged premium in calls and $1.55M in puts. The latest, bearish flow, was on Nov 3, 2026 with $1.99M in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.